ID

40928

Beskrivning

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02267213

Länk

https://clinicaltrials.gov/show/NCT02267213

Nyckelord

Versioner (1)
  1. 2020-06-06 2020-06-06 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

6 juni 2020

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Hepatocellular Carcinoma NCT02267213

Engelsk

Eligibility Hepatocellular Carcinoma NCT02267213

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
radiological diagnosis of hepatic tumor(s) by contrast-enhanced study
Beskrivning

Liver neoplasms Imaging study requiring contrast

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0023903
UMLS CUI [1,2]
C3242003
subjects with advanced hcc who are not eligible for surgical resection or loco-regional therapy.
Beskrivning

Liver carcinoma Advanced | Ineligibility Excision | Ineligibility Therapy Locoregional

Datatyp

boolean

Alias
UMLS CUI [1,1]
C2239176
UMLS CUI [1,2]
C0205179
UMLS CUI [2,1]
C1512714
UMLS CUI [2,2]
C0728940
UMLS CUI [3,1]
C1512714
UMLS CUI [3,2]
C0087111
UMLS CUI [3,3]
C1947913
subjects with sorafenib treatment failure due to sorafenib intolerance or radiographic pd (as per recist v1.1). prior sorafenib use should be ≥ 400 mg/day for at least 14 days.
Beskrivning

Sorafenib failed | Intolerance to Sorafenib | Progressive Disease | Sorafenib U/day

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1516119
UMLS CUI [1,2]
C0231175
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C1516119
UMLS CUI [3]
C1335499
UMLS CUI [4,1]
C1516119
UMLS CUI [4,2]
C0456683
eastern cooperative oncology group (ecog) performance status of ≤ 1
Beskrivning

ECOG performance status

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
child pugh score ≤ 6;
Beskrivning

Child-Pugh - Total Score

Datatyp

boolean

Alias
UMLS CUI [1]
C4055253
a life expectancy of at least 12 weeks or more
Beskrivning

Life Expectancy

Datatyp

boolean

Alias
UMLS CUI [1]
C0023671
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who have received any systemic target therapy or systemic chemotherapy other than sorafenib for the treatment of hcc.
Beskrivning

Targeted Therapy Systemic Liver carcinoma | Systemic Chemotherapy Liver carcinoma | Exception Sorafenib

Datatyp

boolean

Alias
UMLS CUI [1,1]
C2985566
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C2239176
UMLS CUI [2,1]
C1883256
UMLS CUI [2,2]
C2239176
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1516119
subjects who have received sorafenib within 2 weeks prior to the initiation of the treatment dose, or have any sorafenib-related toxicities not yet resolved to grade 1 or baseline.
Beskrivning

Sorafenib Recent | Toxicity Sorafenib Related | Toxicity CTCAE Grades failed

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1516119
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C1516119
UMLS CUI [2,3]
C0439849
UMLS CUI [3,1]
C0600688
UMLS CUI [3,2]
C1516728
UMLS CUI [3,3]
C0231175
subjects who have undergone liver transplantation surgery.
Beskrivning

Transplantation of liver

Datatyp

boolean

Alias
UMLS CUI [1]
C0023911
major surgery within 4 weeks prior to the initiation of the treatment dose (excluding implantation of the intravenous infusion device). percutaneous liver puncture within 2 weeks prior to the initiation of the treatment dose.
Beskrivning

Major surgery | Exception Medical device implantation Intravenous infusion | Puncture of liver Percutaneous

Datatyp

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0877318
UMLS CUI [2,3]
C0021440
UMLS CUI [3,1]
C3698142
UMLS CUI [3,2]
C0522523
Tillbaka till toppen

Similar models

Eligibility Hepatocellular Carcinoma NCT02267213

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Liver neoplasms Imaging study requiring contrast
Item
radiological diagnosis of hepatic tumor(s) by contrast-enhanced study
boolean
C0023903 (UMLS CUI [1,1])
C3242003 (UMLS CUI [1,2])
Liver carcinoma Advanced | Ineligibility Excision | Ineligibility Therapy Locoregional
Item
subjects with advanced hcc who are not eligible for surgical resection or loco-regional therapy.
boolean
C2239176 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1512714 (UMLS CUI [2,1])
C0728940 (UMLS CUI [2,2])
C1512714 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C1947913 (UMLS CUI [3,3])
Sorafenib failed | Intolerance to Sorafenib | Progressive Disease | Sorafenib U/day
Item
subjects with sorafenib treatment failure due to sorafenib intolerance or radiographic pd (as per recist v1.1). prior sorafenib use should be ≥ 400 mg/day for at least 14 days.
boolean
C1516119 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C1516119 (UMLS CUI [2,2])
C1335499 (UMLS CUI [3])
C1516119 (UMLS CUI [4,1])
C0456683 (UMLS CUI [4,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of ≤ 1
boolean
C1520224 (UMLS CUI [1])
Child-Pugh - Total Score
Item
child pugh score ≤ 6;
boolean
C4055253 (UMLS CUI [1])
Life Expectancy
Item
a life expectancy of at least 12 weeks or more
boolean
C0023671 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Targeted Therapy Systemic Liver carcinoma | Systemic Chemotherapy Liver carcinoma | Exception Sorafenib
Item
subjects who have received any systemic target therapy or systemic chemotherapy other than sorafenib for the treatment of hcc.
boolean
C2985566 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C2239176 (UMLS CUI [1,3])
C1883256 (UMLS CUI [2,1])
C2239176 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1516119 (UMLS CUI [3,2])
Sorafenib Recent | Toxicity Sorafenib Related | Toxicity CTCAE Grades failed
Item
subjects who have received sorafenib within 2 weeks prior to the initiation of the treatment dose, or have any sorafenib-related toxicities not yet resolved to grade 1 or baseline.
boolean
C1516119 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C1516119 (UMLS CUI [2,2])
C0439849 (UMLS CUI [2,3])
C0600688 (UMLS CUI [3,1])
C1516728 (UMLS CUI [3,2])
C0231175 (UMLS CUI [3,3])
Transplantation of liver
Item
subjects who have undergone liver transplantation surgery.
boolean
C0023911 (UMLS CUI [1])
Major surgery | Exception Medical device implantation Intravenous infusion | Puncture of liver Percutaneous
Item
major surgery within 4 weeks prior to the initiation of the treatment dose (excluding implantation of the intravenous infusion device). percutaneous liver puncture within 2 weeks prior to the initiation of the treatment dose.
boolean
C0679637 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0877318 (UMLS CUI [2,2])
C0021440 (UMLS CUI [2,3])
C3698142 (UMLS CUI [3,1])
C0522523 (UMLS CUI [3,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial